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METHOD Open Access
Pooled extracellular receptor-ligand
interaction screening using CRISPR
activation
Zheng-Shan Chong1, Shuhei Ohnishi2, Kosuke Yusa2 and Gavin J. Wright1*
Abstract
Extracellular interactions between cell surface receptors are necessary for signaling and adhesion but identifying
them remains technically challenging. We describe a cell-based genome-wide approach employing CRISPR
activation to identify receptors for a defined ligand. We show receptors for high-affinity antibodies and low-affinity
ligands can be unambiguously identified when used in pools or as individual binding probes. We apply this
technique to identify ligands for the adhesion G-protein-coupled receptors and show that the Nogo myelin-
associated inhibitory proteins are ligands for ADGRB1. This method will enable extracellular receptor-ligand
identification on a genome-wide scale.
Keywords: Cell surface receptors, Cell signaling, CRISPR activation, Extracellular protein interactions, Flow cytometry,
Genome-wide screening, G-protein-coupled receptor, Monoclonal antibodies
Background
Identifying cell surface receptors for ligands such as pro-
teins, small molecules, or whole pathogens, is an import-
ant step towards understanding how intercellular
signaling events are initiated and discovering new drug
targets. Because the extracellular regions of receptors
are directly accessible to systemically delivered therapeu-
tics, particularly monoclonal antibodies, these proteins
and their interactions are highly valued targets and
continue to represent a large fraction of currently
approved drugs [1]. However, because solubilizing
membrane-embedded receptor complexes in a solvent
that retains their native conformation is challenging, and
their interaction affinities are often very weak, it is diffi-
cult to detect this class of protein-protein interaction
using most commonly employed methods [2].
One successful approach for large-scale extracellular
interaction screening relies on detecting direct interac-
tions within large libraries of soluble recombinant pro-
teins representing the entire extracellular regions of cell
surface proteins [3–5]. In such assays, bait proteins are
captured in addressed arrays and tested for direct bind-
ing with prey proteins that are oligomerized to increase
local avidity and permit the detection of even very weak
interactions. While this approach has enabled the con-
struction of extracellular protein-protein interaction net-
works [4–6], creating comprehensive libraries containing
thousands of different recombinant proteins is impracti-
cal for most laboratories. In addition, this general
method is largely limited to cell surface proteins that
contain a single contiguous ectodomain which means
that receptors that span the membrane multiple times
are not accessible by this method—a serious limitation
given that they represent over half of all cell surface pro-
teins encoded in the human genome. Together, these
constraints make this approach unsuitable for most la-
boratories who are usually interested in identifying the
receptor for one or a few defined ligands rather than
interaction networks within larger collections of
receptors.
Another successful strategy for receptor identification
uses gain of binding function by overexpressing cDNAs
encoding cell surface receptors in cells. The identity of
the interacting receptor can be determined by an
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iterative expression cloning approach with a suitable
cDNA library [7] or more recently by maintaining large
collections of cloned and sequenced cDNA expression
plasmids [8–10]. While this approach has the advantage
of being able to access different architectural classes of
receptor such as those that span the membrane multiple
times, creating and maintaining comprehensive cDNA
libraries containing thousands of individual clones is
very resource-intensive and so this is not a realistic op-
tion for most laboratories. Other approaches such as
cross-linking chemically derivatized binding probes to
receptors to purify and identify them by mass spectrom-
etry look promising once sufficient amounts of
receptor-expressing cellular material can be isolated [11,
12]. In summary, there is a pressing need for new sys-
tematic approaches to identify receptors for defined li-
gands that encompasses all receptor architectural classes
encoded within the human genome.
The recent development of CRISPR/Cas9-based tools
for transcriptional activation of endogenous genes
(CRISPRa) has enabled convenient genome-scale
cell-based gain-of-function screens to be performed [13,
14]. These methods typically employ a mutant Cas9 pro-
tein that lacks nuclease activity to specifically recruit
transcriptional activators to promoter regions by com-
plexing it with guide RNAs (gRNAs). Libraries of pooled
gRNAs designed to target promoter regions are used to
overexpress individual genes from their endogenous loci
in mammalian cells irrespective of transcript length and
cells displaying the desired phenotype isolated. Import-
antly, these short (~ 20 nucleotides) gRNAs can serve as
molecular barcodes that are easily quantified by modern
sequencing technologies to determine which overex-
pressed gene products are responsible for the desired
phenotype. Here, we use CRISPR/Cas9-based transcrip-
tional activation to target all predicted cell surface pro-
teins encoded in the human genome and establish
experimental parameters for extracellular interaction
screening. We show that this approach can be used to
identify receptors for antibodies and endogenous ligands
with high statistical confidence and systematically screen
for novel extracellular receptor-ligand interactions.
Results
CRISPR activation induces rapid overexpression of cell
surface receptors
CRISPRa upregulates the transcription of gRNA-specified
genes [13–19]; however, few studies have directly investi-
gated its effects on protein abundance within individual cells
and, in the case of cell surface receptors, whether the pro-
teins are displayed on the plasma membrane [20]. Starting
with the synergistic activation mediator approach of Koner-
mann et al. [14], which uses both aVP64 transcriptional acti-
vator fused to the C-terminus of a deactivated Cas9 (dCas9)
protein and recruitment of p65 and HSF1 through an MS2
fusion protein to stem loop structures added to modified
gRNAs, we generated a single plasmid that incorporated all
these elements (Fig. 1a). To determine if CRISPRa can in-
crease cell surface protein expression, we selected a set of 12
receptors not expressed on HEK293 cells, for which mono-
clonal antibodies were available. These included receptors re-
stricted to terminally differentiated cell types such as
erythrocytes (KEL, RHD, SLC4A1) and T-lymphocytes
(CD2). We designed 8 different gRNAs to each of the 12
promoters (Additional file 1: Table S1) and cloned them into
a lentiviral plasmid as a pool for each gene (Additional file 2:
Figure S1a). HEK293 cells were first transduced at a low
multiplicity of infection (MOI) so that each cell typically re-
ceived only a single gRNA from the pool and then trans-
fected the cells with the activator plasmid before quantifying
the level of induced receptor protein overexpression by anti-
body staining using flow cytometry. Elevated cell surface pro-
tein expression was observed within 48 h post-transfection
and was highly variable with only a proportion (up to ~ 30%)
of the transduced cells exhibiting upregulation of the target
receptor and at a wide range of expression levels; this is
shown in detail for SEMA7A and ICAM1 (Fig. 1b) and was
consistently observed for all tested genes (Fig. 1c). Of the 12
receptors tested, an increase in the cell surface protein ex-
pression was observed for eight, including the
T-lymphocyte-restricted CD2 receptor (Fig. 1c). By individu-
ally testing each of the gRNAs targeting the promoter re-
gions of receptors that could be upregulated, we could show
that their efficiency varied significantly: some gRNAs were
unable to upregulate protein expression at all; and for those
that were, they showed heterogeneity both in the brightness
of antibody staining and the proportion of cells stained
(Additional file 2: Figure S1b). Three of the four proteins that
could not be upregulated were restricted to erythrocytes,
suggesting that cell-type specializations such as chromatin
structure, which is known to affect the efficiency of CRISPR
activation [21], precluded surface expression of these pro-
teins in HEK293 cells. Since directing epigenetic modifiers to
enhancer and promoter regions can also induce transcrip-
tional activation [22], we generated a variety of dCas9 fusion
constructs containing combinations of the transcriptional
activator VP64 and the histone acetyltransferase (HAT)
domain of p300, with the aim of improving the efficiency
of receptor upregulation (Additional file 2: Figure S1c).
We found that the addition of p300 HAT domain did not
improve upregulation of erythrocyte-specific proteins
(Fig. 1c). In addition, one of these genes, SLC4A1, showed
more than a 1000-fold increase in mRNA abundance in
the presence of dCas9-VP64 and appropriate gRNAs
(Fig. 1d), suggesting that the lack of protein expression
could be due to a posttranscriptional effect such as
cell-type-specific protein trafficking, rather than the lack
of transcriptionally permissive chromatin structure. In an
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attempt to further increase the efficiency of receptor up-
regulation, we generated a cell line that stably expressed
the double VP64-dCas9-VP64 activator construct and se-
lected a clone that showed the highest CRISPRa activity in
a reporter assay (Additional file 2: Figure S1d). This effi-
cient activator stable cell line (HEK293-V2M) showed an
increase in CRISPRa efficiency compared to transient
transfection with dCas9-activators and exhibited sustained
overexpression for up to 2 weeks post-transduction
(Fig. 1e). These data demonstrate that cell surface receptor
proteins can be upregulated and maintained on the sur-
face of cells using CRISPRa.
Genome-scale enrichment-based extracellular receptor
interaction screening by CRISPRa
To use CRISPRa for genome-wide receptor screening, we
designed a lentiviral library containing gRNAs that tar-
geted the promoter regions of all genes encoding a cell
surface protein in the human genome (Fig. 2a). We se-
lected transcripts encoding proteins predicted to contain a
transmembrane-spanning region, as well as any other pro-
teins with evidence of association with the plasma mem-
brane using lenient thresholds. Transcription start site
(TSS) predictions used were from Gencode v19 TSS
stratified by strict Fantom5 CAGE clusters, and if a gene
a
b d
c e
Fig. 1 CRISPRa induces upregulation of cell surface protein levels. a Schematics of the dCas9 fusion protein and gRNA-dependent recruitment of
the VP64 and MS2-p65-HSF1 transcriptional activators to gene promoter regions (left), and transposon-based plasmids for CRISPR-based
transcriptional activation and non-activating control (right). b Exemplar cytometry plots showing heterogenous upregulation of SEMA7A and
ICAM1 at the surface of HEK293 cells 48 h after transduction at low MOI with a lentivirus-delivered pool of eight gRNAs and transfection with
either activating (dCas9-VP64) or non-activating control (dCas9) plasmids. gRNA positive cells are represented by red dots, gRNA negative cells in
gray. c Quantification of cell surface receptor protein upregulation on cells transduced with lentiviruses encoding gRNAs corresponding to the
appropriate gene using five different dCas9 activator constructs relative to a non-activating dCas9 control. d qRT-PCR analysis of relative mRNA
abundance of indicated target genes in cells 48 h post co-transfection with dCas9-VP64 and either targeting gRNA (+) or no gRNA control.
Transcript abundance was normalized to CYPA expression; bars represent mean ± s.e.m.; n = 6. P values calculated using a Student’s t test, ns P >
0.05; **P≤ 0.01; ***P≤ 0.001. e Percentage of cells expressing the indicated cell surface receptors as determined by mAb staining after
transduction of the cloned activator cell line, HEK293-V2M, with appropriate pooled gRNAs. Data points in c and e represent mean ± s.e.m.; n = 3
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had more than one TSS, the two broadest peaks per gene
were selected for increased sensitivity to alternative
transcripts [23]. Because of the variation in the ability
of individual gRNAs to upregulate cell surface protein
levels, we ensured that the majority of promoter
regions were targeted by seven different guides
(Additional file 2: Figure S2a). The final gRNA library
contained 58,071 guides targeting 6213 genes, along with
500 non-targeting control guides [24]. These 6213 genes
also include intracellular transmembrane proteins, some
of which may be transiently transported to the plasma
membrane. Deep sequencing of the plasmid library and
cells transduced with the same library after 7 days of
culture showed that 89% of guides had read counts within
two orders of magnitude demonstrating that library com-
plexity is maintained (Fig. 2b), and this was retained for
up to 12 days in culture (Additional file 2: Figure S2b).
Individual validation of 34 gRNAs targeting four differ-
ent genes chosen from the library also demonstrated
the success of our design algorithms in selecting guides
capable of inducing cell surface receptor protein upreg-
ulation and additionally demonstrated that the levels of
receptors endogenously expressed by HEK293 cells,
such as CD55, can be further increased (Additional file 2:
Figure S2c, d).
To establish the experimental parameters necessary for
enrichment selections using the genome-wide gRNA li-
brary, we iteratively performed a proof-of-principle screen
using a pool of monoclonal antibodies recognizing eight
different cell surface antigens (Fig. 2a). High CRISPRa activ-
ity HEK293-V2M cells were transduced at a low MOI to
generate a population of cells each overexpressing a differ-
ent cell surface receptor and untransduced cells removed
by BFP expression-based cell sorting after 48 h. 1 × 108
transduced cells were stained with the pool of eight mAbs
and sorted by staining intensity. The relative gRNA
abundance within the selected cells and the original
plasmid library were quantified by deep sequencing and
enrichment analysis performed with MAGeCK [25].
We found that by selecting the brightest 5% of cells
and using a false discovery rate (FDR) of < 0.1, we were
able to unequivocally identify six out of the eight target
antigens with only a single false positive (WNT3),
which would be expected at this significance threshold
(Fig. 2c, Additional file 2: Figure S2e). Accordingly, we
observed clear enrichment in individual gRNAs target-
ing these receptors in sorted cells relative to the plas-
mid library (Fig. 2d). Two target antigens were not
identified (PROM1 and P2RX7) suggesting the guides
in our membrane protein library could not sufficiently
upregulate these proteins. These observations demon-
strate the feasibility of using this approach to unequivo-
cally identify cell surface receptors even within complex
pools of ligands.
Identification of endogenous low-affinity receptor-ligand
interactions by CRISPRa
While we could show that the CRISPRa enrichment ap-
proach successfully identified the binding partners for
antibodies, this class of interactions typically has strong
interaction affinities that can withstand wash steps
thereby facilitating their use in cellular selection assays.
By contrast, interactions between endogenous mem
brane-embedded receptors often have low affinities
which makes detecting them technically challenging
[26]; for example, the CD97-CD55 interaction is ex-
tremely weak (KD ~ 86 μM) [27]. To determine if CRIS-
PRa can be used to identify low-affinity extracellular
interactions, we expressed a panel of recombinant ecto-
domains of cell surface proteins with known receptors of
low affinity (Additional file 2: Figure S3a). The ectodo-
mains of human EFNA1, CTLA4, CD55, and rat Cd200r
were produced as His-tagged, monobiotinylated proteins
and clustered around fluorescently labeled streptavidin
to increase local binding avidity, and used to select
receptor-expressing cells transduced with the membrane
protein CRISPRa library. Clear enrichments of gRNA se-
quences corresponding to expected binding partners for
all ligands were observed at a stringent FDR threshold of
< 0.1 (Fig. 3a–d and Additional file 2: Figure S3b) with
no unexpected receptors demonstrating the low false
positive rate of this approach. Notably, the EFNA1 probe
bound untransduced HEK293 cells (Additional file 2:
Figure S3c) and still identified three Ephrin type-A
receptors (EPHA2, 4, and 7) demonstrating that the
CRISPRa approach can identify multiple receptors in a
single experiment, even though a binding partner is
already expressed by the cell line.
Identification of ligands for adhesion G-protein-coupled
receptors
Adhesion G-protein-coupled receptors (GPCRs) form a
large subgroup of the GPCR superfamily, which is a
major class of drug targets. Adhesion GPCRs have di-
verse functions including immune regulation [28, 29],
central nervous system development [30], and angiogen-
esis [31, 32]. These receptors have large extracellular
N-terminal regions containing protein domains involved
in adhesion [33] and a conserved GPCR proteolysis site
(GPS) within an autoproteolysis-inducing domain [34].
These receptors can be activated by ligand binding
which relieves the auto-inhibitory action of the receptor
ectodomain [35, 36]; crucially, activating ligands for the
majority of adhesion GPCRs are not known. To
characterize adhesion GPCR ligands, we expressed the
entire ectodomains of adhesion GPCRs as soluble
recombinant monobiotinylated proteins by mutating the
GPS site to prevent proteolysis, made highly avid
fluorescent binding probes, and screened by enrichment
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CRISPRa to identify ligands (Additional file 2: Figure S4a, b).
At the stringent significance threshold (FDR < 0.1), we identi-
fied binding partners for four receptors which included pre-
viously reported interactions between members of the
Latrophilin subfamily (ADGRL1 and 3) with FLRT proteins
[30] and Tenurins [37] (Fig. 4a). For selections with
ADGRA2, we observed an enrichment of guides target-
ing Syndecans (SDC1 and SDC2), a family of heparan
sulfate proteoglycans, which is consistent with known
interactions of ADGRA2 with glycosaminoglycans [38]
(Fig. 4a). Using ADGRB1 as a selection probe, we ob-
served an enrichment of guides targeting two members
of the Reticulon 4 receptor family, RTN4RL1 and 2
(Fig. 4b, Additional file 2: Figure S4c). ADGRB1 (brain
angiogenesis inhibitor 1, BAI1) is a phosphatidylserine
receptor on professional phagocytes [39] and is enriched
in the postsynaptic density in neurons where it regulates
excitatory synapse formation in hippocampal and cortical
cultures [40] but has no documented ligands in the
nervous system. RTN4RL1 and RTN4RL2 (Nogo
receptor-like 2 and 3) are both glycosylphosphatidyli-
nositol (GPI)-linked membrane proteins and known to
be involved in regulating axon growth and synapse forma-
tion, most notably through interactions between RTN4R
and the myelin-associated inhibitor, Nogo-66 [41]. To ver-
ify these interactions, we individually overexpressed all
three members of the Nogo receptor family by transfect-
ing HEK293 cells with cDNA expression plasmids and
confirmed gain of cell surface binding with ADGRB1
(Fig. 4c), and demonstrated that this gain of ADGRB1 bind-
ing was not due to increased levels of exposed phosphatidyl-
serine on transfected cells (Additional file 2: Figure S4d). To
show that the ectodomains of ADGRB1 and RTN4Rs dir-
ectly interacted, we expressed the extracellular domains of
ADGRB1 and RTN4Rs as either soluble recombinant mono-
meric biotinylated “baits” or pentameric “preys” suitable for
Fig. 2 Genome-scale enrichment-based extracellular interaction screen identifies multiple antibody targets. a Workflow of CRISPRa screen for
identifying extracellular interactions. b Ranked gRNA abundance in the plasmid library and cells transduced with the CRISPRa lentiviral library and
cultured for 7 days as determined by raw read counts from deep sequencing of PCR-amplified products. c Plot of transformed P values versus
genes in enriched rank order from cells selected using a pool of mAbs targeting eight cell surface proteins: CD2, ITGB3, CD200, VCAM1, ENG,
ICAM1, P2RX7, and PROM1. Genes with a false discovery rate (FDR) ≤ 0.1 are indicated with a red dot and labeled. WNT3 was identified as a false
positive at this stringency threshold, and P2RX7 and PROM1 as false negatives. d Comparison of gRNA sequencing read counts in fluorescence-
sorted cells versus the original plasmid library. gRNA targeting the eight genes and WNT3 are denoted with different shapes, gray dots represent
gRNA targeting the promoter regions of all other genes. FN, false negative; FP, false positive; TP, true positive
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avidity-based extracellular interaction screening (AVEXIS)
[3]. We observed that ADGRB1, but not the closely related
ADGRB2, interacted directly with all three members of the
RTN4R family in both bait-prey orientations (Fig. 4d) and
showed that the N-terminal thrombospondin type 1 repeats
1–3 on ADGRB1 were sufficient for this binding (Fig. 4e).
Discussion
We have developed a pooled cell-based screening ap-
proach to identify extracellular protein interactions by
overexpression of cell surface receptors using CRISPR
activation. Existing technologies for large-scale inter-
action screening such as AVEXIS or cDNA overexpres-
sion arrays require creating and maintaining large
reagent collections containing thousands of individual
plasmids and proteins, representing a significant invest-
ment of time and resources. Pooled CRISPRa screening
overcomes this difficulty by relying on less costly pooled
libraries of short gRNA for endogenous upregulation of
surface receptors and requires only one round of selec-
tion in a single tube. Additionally, the cell-based aspect
of CRISPRa screening provides an advantage over re-
combinant protein-based assays by allowing the
investigation of a wider range of cell surface receptors,
for instance those with multiple transmembrane do-
mains or heteromeric receptors. CRISPRa differs from
cDNA overexpression through its targeting of endogen-
ous promoters, thereby capturing the variety of isoforms
that would be natively transcribed, which could be favor-
able for agnostic, large-scale screening [10]. The use of a
single, easy to transduce activator cell line for CRISPRa
screening and the ability to detect multiple receptors re-
gardless of endogenous expression also provides an ad-
vantage over CRISPR loss-of-function approaches to
identify receptors [42] in situations involving more com-
plex binding profiles, or ligand-binding to specialized
cell types, which can be difficult to transduce on the
scale required for CRISPR/Cas-9 screening.
We demonstrated the ability of this approach to accur-
ately identify known extracellular protein interactions
using both high-affinity mAbs and endogenous
receptor-ligand interactions with a low false positive
rate. Using a fixed significance threshold for all our ex-
periments, we observed only one unexpected interaction:
the identification of WNT3 from a selection using a pool
of antibodies. This gene was identified at a lower
Fig. 3 Unequivocal identification of low-affinity endogenous receptor-ligand interactions using CRISPRa. Transformed gene-level enrichment P
values are plotted against rank-ordered genes for receptor CRISPRa cell selections performed using the ectodomains of EFNA1 (a), CD55 (b),
CTLA4 (c), and rat Cd200r (d). Screens were conducted in duplicate
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Fig. 4 Genome-wide CRISPRa selections identified known and novel ligands for adhesion GPCRs. Transformed gene enrichment P values plotted
against a rank-ordered gene list for CRISPRa enrichment screens with cells selected using adhesion GPCR recombinant binding probes for
ADGRL1, ADGRL3, and ADGRA2 (a), and ADGRB1 (b). A single screen was performed for each adhesion GPCR bait. c A highly-avid fluorescently
labeled ADGRB1 binding probe stained cells transfected with cDNAs encoding full-length RTN4R, RTN4RL1, and RTN4RL2 (blue lines) but not
mock-transfected cells compared to a control ADGRL1 binding probe (orange line), or streptavidin-phycoerythrin alone (red line). A representative
of four independent experiments is shown. d The ectodomains of ADGRB1 and RTN4R family members directly interact. The extracellular regions
of the named receptors were expressed as soluble biotinylated bait proteins, captured in individual wells of a streptavidin-coated plate and
probed for interactions with pentameric beta-lactamase-tagged prey proteins using AVEXIS. Binding is quantified by absorbance at 485 nm of a
hydrolysis product of the colorimetric beta-lactamase substrate, nitrocefin. Bars represent blank-subtracted mean ± s.d; n = 3. CD97-CD55
interaction was used as a positive control; negative control bait was the CD55 ectodomain. e The RTN-family binding interface on ADGRB1 is
composed of the N-terminal three TSR domains. Schematic of the RTN-family and ADGRB1 proteins showing their domain organization. Binding
of RTN4R and RTN4RL1 preys to fragments of ADGRB1 encompassing the full-length ectodomain (FL), thrombospondin repeats 1–3 (TSR1–3),
TSRs 1–5, or the hormone receptor motif and GAIN domain (HRM+GAIN). Bars represent mean ± s.d.; n = 3
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threshold than the other targets and may be due to anti-
body cross-reactivity which is not infrequently observed
[43]. In some instances, we were unable to detect en-
richment of all expected binding partners including
CD86 for CTLA4 and one member of the RTN4R family
for ADGRB1. Given that we know the selection probe
was active in both these instances, these false negatives
are likely to be due to the failure to upregulate these re-
ceptors at the cell surface. Based on our observations,
this could be due to gRNAs targeting inaccessible pro-
moter regions, alternative or cryptic TSSs, TSS mispre-
diction, or a lack of accessory factors for functional
presentation on the surface. An additional possibility is
that the receptor may be expressed on the surface, but
lacks the necessary components for proper folding and
binding to its endogenous ligands. The issues of TSS
misprediction and inactive guides are not shared with
existing technologies such as cDNA overexpression,
highlighting the importance of complementary screening
approaches. Nonetheless, this approach should improve
with advances in activating gRNA design for CRISPRa,
better TSS prediction, and the use of cell lines other than
HEK293 cells for screening. Although we did not observe
this with the HEK293 cells used here, the expansion of
transduced cell libraries may also result in a loss of guides
targeting receptors that cause cell toxicity or growth dis-
advantages when overexpressed in other cell lines.
Using this CRISPRa approach, we identified a novel
set of receptor-ligand interactions between ADGRB1
and members of the RTN4R family. The genes encoding
all interacting proteins exhibit enriched expression in
the brain, and all have documented functions in the
regulation of neurite growth and synapse formation both
in vitro and in vivo [40, 44]. The RTN4R family of pro-
teins is known to function redundantly with regard to
regulating neuronal growth in vivo [44], and therefore,
the discovery of common binding partners may provide
an explanation for this functional redundancy.
Potential applications for extracellular interaction pro-
filing using CRISPRa are not restricted to proteins such
as antibodies or recombinant proteins, but could be used
with any selectable probe ranging from small molecules
to whole pathogens such as virions or bacteria. Ideally,
selection probes would be fluorescently labeled, although
this approach should also be compatible with cell viabil-
ity assays. Because the selection and activation effect are
compartmentalized in individual cells, all potential re-
ceptors for a given binding probe can, in principle, be
identified in a single experiment, even for very complex
samples such as polyclonal antibody profiles in serum.
Conclusions
Identifying extracellular protein interactions between
membrane-embedded receptors remains technically
challenging because they often have weak interaction af-
finities, and their amphipathic character makes them dif-
ficult to solubilize in their native conformation. Existing
methods to detect this class of protein interaction are
impractical for most laboratories because they require
creating and maintaining thousands of individual plas-
mids and proteins, lack genome-wide coverage, and are
usually restricted to the receptor architectural class that
span the membrane a single time. The approach we de-
scribe here combines existing strategies of increasing
interaction avidity by multimerization with transcrip-
tional upregulation by CRISPRa to provide a method
that is cheaper and easier to implement than existing ap-
proaches and obviates the need to compile large reagent
resources. Since extracellular protein interactions can be
targeted by systemically delivered drugs, we envisage
that this approach will be very useful to identify novel
drug and vaccine targets for genetic and infectious
diseases.
Methods
Generation of different dCas9 fusion constructs
Expression plasmid pPB-R1R2_EF1adCas9VP64_T2A_MS2
p65HSF1-IRESbsdpA was constructed as follows: dCas
9VP64_Blast (BsiWI-EcoRI fragment from Addgene 61425)
and MS2p65HSF1_hyg (BsiWI-EcoRI fragment from
Addgene 61426) were first transferred into pKLV2-EF1a
[45], after introducing the BsiWI-EcoRI site between AscI
and NotI sites, resulting in pKLV2-EF1adCas9VP64T2
ABsd-W and pKLV2-EF1aMS2p65HSF1hyg-W, respectively.
To combine dCas9VP64 and MS2p65HSF1 via T2A
peptides, PCR-generated BsiWI-EcoRI fragment carrying
T2A and BsrGI-flanked GFP was cloned into the
BsrGI-EcoRI site of pKLV2-EF1dCas9VP64T2ABsd-W and
then the BsiWI-BsrGI fragment of pKLV2-MS2p65HSF
1T2Ahyg-W, which carries MS2p65HSF1, was inserted into
the BsrGI site, resulting in pKVL2-EF1adCas9VP64
-t2AMS2p65HSF1-W. In parallel, pENTR-EF1a-GFP_AscIE-
coRI-IRESneo was generated as follows: the SalI-HindIII
fragment carrying EF1a from pENTR-EF1aCas9-IRESneo
[45] and the AscI-NotI-HapI linker were cloned into the
SalI-NotI site of pENTR-EF1aCas9-IRESneo, resulting in
pENTR-EF1a-ANH-IRESneo, and then the PCR-generated
AscI-GFP-EcoRI-NotI fragment was cloned into the
AscI-NotI site of pENTR-EF1a-ANH-IRESneo. The
AscI-EcoRI fragment carrying dCas9VP64T2AMS2p65HSF1
was cloned into pENTR-EF1a-GFP_AscIEcoRI-IRESneo,
resulting pENTR-EF1adCas9VP64_T2A_MS2p65HSF1-IRE
SneopA. The drug selection marker IREneopA was replaced
with PCR-generated IRESbsdpA between EcoRI and SpeI
sites, resulting pENTR-EF1adCas9VP64_T2A_MS2p65HSF
1-IRESbsdpA. Lastly, the insert in the entry vector,
pENTR-EF1adCas9VP64_T2A_MS2p65HSF1-IRESbsdpA,
was transferred to pPB-R1R2-EM7NeoPheS [46] by the
Chong et al. Genome Biology          (2018) 19:205 Page 8 of 16
Gateway cloning, resulting pPB-R1R2_EF1adCas9VP64_
T2A_MS2p65HSF1-IRESbsdpA.
Expression plasmid pMCV-EF1a_grow_dCas9-GFP_
Blast_pA was a kind gift from Mathias Friedrich (Sanger
Institute). The histone acetyltransferase p300 core used
in Hilton et al. [22] was synthesized as several gBlock
DNA fragments (Integrated DNA Technologies) with
homology arms for insertion into lenti dCAS-VP64_
Blast (Addgene plasmid #61425). C-terminal insertion
(relative to dCas9) of the p300 core domain into the lin-
earized lenti dCAS-VP64_Blast plasmid was constructed
with the corresponding gBlock DNA fragments using
Gibson assembly and the resulting plasmids digested
with XbaI. This enabled insertion of the MS2p65HSF1
construct from plasmid pPB-R1R2_EF1adCas9VP64_
T2A_MS2p65HSF1-IRESbsdpA. The resulting dCas9-
fusion-T2A-MS2p65HSF1 plasmids were subsequently
cloned into a kanamycin-resistant pENTR-EF1a-IRESbsd
entry vector using restriction enzyme digest with BsiWI
and EcoRI (NEB). VP64 or p300 domains were inserted
5′ of the dCas9 coding sequence in the pENTR-
EF1a-IRESbsd entry vector by Gibson assembly. Gateway
cloning was performed to transfer the dCas9-fusion-
T2A-MS2p65HSF1 constructs into the final ampicillin-
resistant expression plasmid pPB-R1R2-IRESbsdpA.
VP64 fragments were PCR amplified from lenti
dCAS-VP64_Blast. NEBuilder HiFi DNA Assembly
Cloning Kit (NEB) was used for all Gibson assembly re-
actions and conducted according to the manufacturer’s
protocol. All plasmids were sequence-verified.
All enzymatic digestions were performed in 50 μL
reaction volumes with 5 μg DNA, 5 μL 10× digestion
buffer, 1 μL of each restriction enzyme, and incubated
at 37 °C for at least 6 h. 5′ dephosphorylation was
achieved by incubation with Antarctic Phosphatase
(NEB) for 30 min at 37 °C followed by inactivation for
5 min at 80 °C. Digested products were separated by gel
electrophoresis on a 1.2% agarose gel and the required
fragments purified using Qiagen Gel Purification kit
(Qiagen).
PCR reactions for generating VP64 fragments were
performed in 25 μL reaction volumes with 12.5 μL 2×
Q5 Hotstart Hifi Master Mix (NEB), 1 μL each 10mM
sense and anti-sense primers, 1 μL (1 μg) template DNA,
and 9.5 μL nuclease-free water (Ambion). The PCR reac-
tions were performed in a Tetrad 2 Thermal Cycler
(Bio-Rad), and cycling conditions were as follows: 30 s at
95 °C for initial denaturation, followed by 25 cycles of 30
s at 95 °C for denaturation, 30 s at 60 °C for annealing,
90 s at 72 °C for extension, and 5min at 72 °C for the
final extension. Purification of PCR products was per-
formed with Qiagen PCR Purification kit (Qiagen). All
sequencing primers, PCR primers and gBlock sequences
are listed in Additional file 1: Table S2.
Individual guide RNA design
Guide RNA (gRNA) targeting IL1RN previously pub-
lished in [22] were used as positive controls for tran-
scriptional activation. For the panel of 12 cell surface
receptors, potential guides were identified and ranked
using CRISPR-ERA. CRISPR-ERA ranks sequences using
an on-target S-score based on distance to the transcrip-
tional start site (TSS), and an off-target E-score based on
the number of off-target sites [47]. Eight non-
overlapping guides most proximal to the TSS of the lon-
gest RefSeq isoform were chosen for each gene. Guides
targeting the same gene were cloned as a pool using One
Shot TOP10 Chemically Competent E. coli (Invitrogen)
and propagated in liquid culture. In all other experiments,
guides were cloned individually and sequence verified be-
fore lentiviral production or transfection into cells.
Individual gRNA cloning
Expression vector of gRNA with an improved scaffold
[48] and MS2-binding hairpin loops was constructed by
replacing the MluI-BamHI fragment of pKVL2-
U6gRNA5(BbsI)-PGKpuroBFP-W [45] with a gBlock
fragment containing the human U6 promoter-driven
SAM-gRNA cassette with the BbsI cloning site, resulting
pKVL2-U6gRNA_SAM(BbsI)-PGKpuroBFP-W.
Individual guides were synthesized as 24 bp oligomers
(Sigma Aldrich and IDT) containing complementary over-
hangs to those generated by BbsI digestion of the gRNA ex-
pression vector. These oligomers were 5′ phosphorylated
with T4 PNK (NEB) for 30min at 37 °C before annealing in
1× T4-ligation buffer (NEB) for 50min at 95 °C before slowly
decreasing the temperature to 25 °C at 0.1 °C/s. Annealed oli-
gos were ligated into the lentiviral gRNA vector by incubat-
ing withT4 DNA Ligase (NEB) for 4 h at 16 °C.
Membrane protein gRNA library design
A non-redundant list of 6213 genes encoding membrane
proteins were compiled from five sources using lenient
thresholds: a mass-spectrometry derived Cell Surface Atlas
[49], a bioinformatic construction of the surfaceome [50], a
manually curated list of proteins with experimentally veri-
fied cell surface localization kindly provided by Laura
Wood (Sanger Institute), the transmembrane protein
cDNA collection (Origene), and the Human Protein Atlas
(filtered for location: plasma membrane) [51]. TSS predic-
tions were selected from Gencode v19 TSS stratified by
strict Fantom5 CAGE clusters, and the two broadest peaks
per gene were selected [23]. For genes that were not associ-
ated with a CAGE peak, ENSEMBL transcripts annotated
as “principal” in the APPRIS database were selected instead.
Where no transcripts with this criterion were found, all
RefSeq transcripts with NM accession numbers were se-
lected. Promoter region sequences (450–50 bp upstream of
each TSS) were obtained from the human assembly
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hg19 in Ensembl using the BiomaRt package. All 19
nucleotide sequences adjacent to an NGG protospacer
adjacent motif (PAM) within these sequences were
identified. Guides with < 30% or > 75% GC content,
polyT sequences (> 3 Ts), or BbsI restriction sites
were discarded, and the resulting guides were ranked
according to proximity to the TSS peak. Each guide
was mapped using BLAT to all promoter regions tar-
geted and guides with exact matches to promoters
other than their intended target were removed, with
the exception of those targeting genes with shared
promoter regions or gene families with similar pro-
moter sequences. As far as possible, seven guides
were selected per transcript/peak. Where a gene had
six guides or fewer, rules concerning GC content and
polyT stretches were relaxed such that every tran-
script had at least two guides, with only eight genes
having two guides per gene. To ensure a high level of
transcription by the U6 promoter, a guanine nucleo-
tide was added to the 5′ end of all guide sequences.
Five hundred non-targeting control gRNA sequences
were selected from gRNA sequences previously pub-
lished [24] and were designed to have no binding
sites in the human genome (up to two mismatches).
All gRNA sequences are listed in Additional file 3.
Membrane protein gRNA library cloning
Fifty-eight thousand five hundred seventy gRNA se-
quences were synthesized as a complex pool of 77-mer
single-stranded DNA oligos (Twist Biosciences). The
sequence of each 77-mer oligo was 5′ GCAGATGGC
TCTTTGTCCTAGACATCGAAGACAACACCGN19 G
TTTTAGTCTTCTCGTCGC where N19 represents dif-
ferent 19 bp guides. Double-stranded DNA was ampli-
fied from 40 ng of ssDNA oligos using primer pair
77-mer_U1 and 77-mer_L1 (Additional file 1: Table S2).
Each reaction contained 1 ng ssDNA, 1.25 μL of each
primer at 10 μM, 12.5 μL Q5 2× High Fidelity Hot-start
Master Mix (NEB), and nuclease-free water to a final
volume of 25 μL. Cycling conditions were as follows: 30
s at 98 °C for enzyme activation, followed by 8 cycles of
10 s at 98 °C for denaturation, 15 s at 63 °C for annealing,
15 s at 72 °C for extension, and a final extension for 2
min at 72 °C.
PCR products were purified using Qiagen Nucleotide
Removal kit (Qiagen) and digested with BbsI (NEB)
overnight. Digested fragments were separated on a 20%
TBE PAGE gel (Invitrogen) at 200 V for 1.5 h and the
guide-containing 24 bp fragment excised and purified
using the crush-and-soak method in 0.3 M NaCl
overnight, followed by ethanol precipitation and resus-
pension in TE. DNA bands in polyacrylamide gels were
visualized by incubating the gel in 0.5 μg/mL ethidium
bromide for 10 min followed by ultraviolet light
exposure on a transilluminator. Ligation of the mem-
brane protein gRNA library into the pKLV2-U6gRNA_
SAM(BbsI)-PGKpuroBFP-W expression vector was
performed at a 1:5 insert to vector ratio with T4 DNA
Ligase for 2 h at 25 °C and transformed into One Shot
TOP10 Chemically Competent E. coli (Invitrogen) by
heat shock at 42 °C. The total number of colony-forming
units was estimated, by plating dilutions of the trans-
formed cells, to be 11× the complexity of the library.
Transformants were cultured in a liquid culture and
DNA preparation performed using a PureLink HiPure
Plasmid Filter Maxiprep Kit (Invitrogen), according to
the manufacturer’s instructions. To determine the distri-
bution of gRNA in the plasmid library, 10 ng of the plas-
mid preparation (~ 1 × 109 copies) were used for
Illumina sequencing.
RNA isolation and q-RT-PCR
Relative mRNA expression levels were quantified by re-
verse transcription and quantitative PCR (qPCR). Total
RNA was isolated from approximately 5 × 106 cells per
sample using TRIzol Reagent (Ambion) according to the
manufacturer’s protocol. One microgram of total RNA
was reverse transcribed using SuperScript III First-
Strand Synthesis Kit (Invitrogen), treated with RNase H
for 20 min at 37 °C to remove remaining RNA, and the
resulting cDNA diluted 30-fold in nuclease-free water.
qPCR was performed using Sensimix SYBR Low-Rox Kit
(Bioline) with 5 μL of diluted cDNA in a final reaction
volume of 15 μL. Samples were prepared in 384-well for-
mat with two technical replicates for every RNA sample
and cycled on a LightCycler 480 Instrument II. Cycling
parameters were as follows: 10min at 95 °C for polymer-
ase activation, followed by 40 cycles of 15 s at 95 °C for de-
naturation, 15 s at 55 °C for annealing, and 15 s at 72 °C
for extension. A melt-curve analysis (from 25 to 95 °C)
was performed at the end of the run to check for the pres-
ence of primer-dimers or other unwanted products.
Primers annealing to GAPDH and CYPA have been
previously published and were used as housekeeping con-
trols [22, 52]. All other primers were designed using
Primer-BLAST, with the exception of IL1RN primers
which were previously published in [15]. All qPCR
primers used are listed in Additional file 1: Table S2.
Threshold cycle (Ct) values were determined by the num-
ber of cycles needed to reach an arbitrary fluorescence
threshold set just above baseline. Relative mRNA expres-
sion was determined using the 2ΔΔCt method where
target Ct values were first normalized to GAPDH and
CYPA Ct values. Fold changes in target gene mRNA levels
were determined by comparing to mock-transfected ex-
perimental controls. All q-RT-PCR primers used are listed
in Additional file 1: Table S2.
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Recombinant ectodomain construct design
Members of the adhesion GPCR (aGPCR) family were
selected for expression based on the following criteria:
they possessed a high-scoring signal peptide prediction
by SignalP 4.0, lacked known extracellular cleavage sites
other than the GPCR proteolysis site (GPS), and had
extracellular domains (ECDs) of less than 2000 amino
acids. Where the His-Leu-Thr/Ser cleavage sequence in
the GPS domain was conserved, a Thr/Ser to Gly
mutation was introduced to prevent self-cleavage [34].
Mammalian expression plasmids encoding the entire
predicted extracellular region except the signal peptide
were synthesized (GeneArt, Invitrogen) and subcloned
into both a “bait” plasmid (pMero-Cd4d3+4-BioLHis -
Addgene plasmid 50812) producing a monomeric enzy-
matically monobiotinylated bait when co-transfected
with a plasmid encoding a secreted BirA protein
(Addgene plasmid 64395), and a “prey” plasmid (pMer-
o-Cd4d3+4-COMP-blac-FLAGHis) which produces a
highly avid pentameric beta-lactamase-tagged protein [3,
53]. Both plasmids contained an exogenous signal pep-
tide that facilitates protein secretion, domains 3 and 4 of
rat Cd4 as an antigenic tag, and a polyhistidine-
sequence for purification [54, 55]. These tags were used
for relative quantification and normalization of proteins,
as well as forming oligomers for increased avidity.
The GPI-anchor attachment residue of RTN4R,
RTN4RL1, and RTN4RL2 was predicted with PredGPI and
the entire extracellular regions, including the endogenous
signal peptides, were amplified from full-length cDNA con-
structs (Origene) by PCR (Additional file 1: Table S2) and
cloned into bait and prey expression vectors pTT3-Cd4d3
+4-BLH (Addgene plasmid 36153) and pTT3-Cd4d3
+4-COMP-blac-FLAGHis (Addgene plasmid 71471).
Cell lines and culture
Suspension and serum-free adapted HEK293-6E cells were
routinely cultured in Freestyle media (Invitrogen) supple-
mented with 25 μg/mLG418 (Invitrogen) and 0.1% Kolli-
phor and in Freestyle media supplemented with 50 μg/mL
G418 and 1% FBS (Invitrogen) after single-cell cloning.
Cells were maintained in suspension in shaking incubators
at 125 rpm and passaged every 2–3 days. To select stable
dCas9-expressing cell lines for screening, HEK293-6E cells
were transfected with pPB-R1R2_EF1adCas9VP64_T2A_
MS2p65HSF1-IRESbsdpA or pPB-R1R2_EF1aVP64dC
as9VP64_T2A_MS2p65HSF1-IRESbsdpA, along with a
hyperactive piggyBac transposase (hyPBase) in a 1:5 ratio
of transposase to transposon vector. Selection with Blasti-
cidin S (TOKU-E) at 5 μg/mL was initiated 48 h post
transfection. Only cells transduced with pPB-R1R2_
EF1aVP64dCas9VP64_T2A_MS2p65HSF1-IRESbsdpA
and hyPBase gave rise to stable cell lines and were
single-cell sorted into 96-well plates with a BD Influx cell
sorter (BD Biosciences). Genomic integration was con-
firmed by PCR with primers targeting the transgene as
well as flanking vector regions. This cell line is henceforth
referred to as HEK293-V2M, where V2M stands for dCas9
with VP64 × 2 and MS2p65HSF1. Clonally derived lines
were expanded, and the clone with the highest CRISPRa
activity as evaluated using the CRISPRa GFP reporter
assay was selected. All cell lines used in this project were
tested and found negative for mycoplasma contamination
(Surrey Diagnostics). For cDNA overexpression experi-
ments, plasmids expressing full-length RTN4R, RTN4RL1,
and RTN4RL2 were purchased from Origene and trans-
fected into HEK293-6E cells using PEI.
CRISPRa GFP reporter assay
To quantitative CRISPRa activity, we developed a cell-based
reporter assay: briefly, each construct encodes BFP under a
constitutive PGK promoter and GFP driven by a minimal
CMV promoter preceded with a tetracycline response elem-
ent (TRE). The empty reporter encodes a non-targeting
guide while the reporter encodes a guide complementary to
the TRE, such that when expressed in a cell with an active
CRISPRa system, the TetO reporter induces an increase in
levels of GFP while the “Empty” reporter does not. To con-
struct the empty control vector, the TRE-minimal promoter
from pTRE-tight (Clontech), GFP, and U6gRNA_SAM(BbsI)
were cloned into the MluI-BamHI site of pKLV2-
U6gRNA5(BbsI)-PGKpuroBFP-W [45], resulting in pKLV2-
U6gRNA_SAM(BbsI)-TREGFP-PGKpuroBFP-W. sgTetO
(5′-GACGTTCTCTATCACTGATA-3′) was cloned into
the BbsI site, resulting in pKLV2-U6gRNASAM(gTetO)-
TREGFP-PGKpuroBFP-W.
HEK293-6E cells expressing the dCas9/p300/VP64 var-
iants and MS2p65HSF1 fusion proteins were transduced
with lentiviruses carrying either reporter, and GFP/BFP
expression was analyzed 72 h post transduction by flow
cytometry on a BD LSRFortessa flow cytometer (BD Bio-
sciences) as a measure of activation efficiency.
Lentiviral production and transduction
HEK293-FT cells used for lentivirus packaging were
maintained in DMEM with GlutaMAX supplemented
with 10% FBS (Invitrogen) and 1% penicillin-strep
tomycin and passaged every 2–3 days. For virus pro-
duction, 5 × 106 cells were seeded in a 10-cm plate at
day 0 and transfected with 3 μg of transfer plasmid,
9 μg ViraPower lentivirus packaging vectors (Invitro-
gen) using 36 μl Lipofectamine LTX and 12 μl PLUS
reagent diluted in Opti-MEM I (Invitrogen) transfection
media. Cells were incubated for 4 h at 37 °C in transfection
media before changing to DMEM with 10% FBS. Viral
supernatant was harvested 2 days later, filtered, aliquoted,
and stored at − 80 °C. Transduction of other cell lines was
performed by incubating with a defined volume of virus
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overnight at 37 °C. Viral titers were determined by trans-
ducing HEK293-6E cells with a serial dilution of viral
supernatant and quantifying the percentage of BFP-
expressing cells on day 2 post-transduction by flow cytom-
etry. Before performing pooled screens, viruses were
titered to achieve a multiplicity of infection (MOI) of 0.3;
however, it was found that performing small-scale infec-
tions in 96-well plates did not scale up linearly, resulting
in a higher level of infection than calculated. Instead,
1 × 107 HEK293-V2M cells were transduced with three
different volumes of library virus by overnight incubation
at 37 °C. Cells were analyzed 2 days post-transduction by
flow cytometry, with BFP as a marker for successful trans-
duction, and the volume of virus which resulted in
25–30% BFP-positive cells was chosen. This process
was repeated with each batch of virus produced.
For screening, 4 × 107 HEK293-V2M cells were trans-
duced to achieve between 25 and 30% BFP-positive cells
(~ 0.3 MOI corresponds to 200× library coverage). An
MOI of 0.3 ensured that the majority of infected cells re-
ceive one virus per cell. Transduced cells were sorted on
day 2 post-transduction on a MoFlo XDP cell sorter
(Beckman Coulter) and BFP-positive cells collected. Be-
tween 1.0–1.6 × 107 cells were collected for each trans-
duction (166×–266× library coverage) and maintained in
media supplemented with 2 μg/mL puromycin (Gibco)
to maintain lentiviral construct expression. To deter-
mine the effect of gene activation on cell growth, 6 × 107
cells (1000× library coverage) were sampled on days 7,
10, and 12 post-transduction. To compare the distribu-
tion of gRNAs in the transduced library with that in the
original plasmid library, as well as between different
virus preparations, 6 × 107 cells were sampled on day 7
post-transduction with either virus preparation. Al-
though one might expect to see clusters of interacting
cells in the library culture caused by the interaction of
upregulated receptors, we did not observe any increase
in cell aggregation, possibly due to the shear forces pro-
duced from this cell line being grown with constant
shaking (125 RPM).
Comparison of dCas9 activators with p300 and VP64
5 × 106 cells were transduced at < 0.3 MOI, with
lentivirus-packaged gRNA pools, with each pool of 8
gRNAs targeting one of 12 surface proteins. This was to
mimic screening conditions as closely as possible and to
avoid synergistic activation caused by the expression of
multiple gRNAs targeting the same gene in one cell.
Transduction was carried out by incubating viral su-
pernatants with cells at 37 °C overnight (~ 16 h). The
next day, cells were reverse-transfected with respect-
ive dCas9-activator expression constructs using Lipo-
fectamine LTX and PLUS Reagent (Invitrogen) in a
96-well format and grown for an additional 48 h
before analysis by antibody staining and flow cytome-
try. Transfection efficiency was estimated to be be-
tween 70 and 80% from analysis of cells transfected
with the non-activating control expressing
dCas9-eGFP (data not shown).
Flow cytometry and fluorescence activated cell sorting
Hybridoma supernatants were obtained from either the
International Blood Group Reference Laboratory
(National Health Service, UK) or the Developmental Studies
Hybridoma Bank (University of Iowa, USA). Purified
antibodies were purchased from Abcam, Merck Milli-
pore, or Biolegend. All antibodies used for flow cyto-
metric analysis, along with their provenance, are listed
in Additional file 1: Table S3. For immunofluorescent
staining, 100 μL of 1 μg/mL primary antibody was incu-
bated with 5 × 105 cells for 1 h at 4 °C. Cells were then
washed 1× in PBS-1% BSA before incubation with
100 μL of 0.1 μg/mL phycoerythrin (PE)-conjugated
secondary for 1 h at 4 °C. Finally, cells were washed 1×
with PBS-1% BSA before being resuspended in PBS
without carrier protein and analyzed by flow cytometry.
Resuspending in PBS-1% BSA increased the occurrence
of instrument blockage, causing fluctuations in fluores-
cence intensity during acquisition. Samples were
analyzed on a LSRFortessa flow cytometer (BD Biosci-
ences), and the resulting data were analyzed using
FlowJo (BD Biosciences).
To detect gain-of-function binding to recombinant
protein probes or antibodies, 1 × 108 HEK293-V2M cells
were assayed between days 7–10 post-transduction. Cells
were washed once in PBS-1% BSA, then incubated with
5 mL normalized recombinant protein or 1 μg/mL pri-
mary antibodies for 2 h on ice. Cells were washed again
with PBS-1% BSA and then incubated in secondary,
PE-conjugated antibodies for 1 h on ice. Cells were
washed a final time in PBS-1% BSA before cell sorting.
For pre-conjugated bait proteins which had been oligo-
merized around streptavidin-PE, only a single incubation
was performed for 2 h on ice. Labeled cells were resus-
pended in PBS and sorted using a SH800 cell sorter
(Sony Biotechnology). Double positive BFP+PE+ cells
were collected and stored at − 20 °C before gDNA ex-
traction and sequencing. We have found that recovering
a minimum of 1 × 106 cells from sorting approximately
1 × 108 cells at a 5% threshold is needed for reliably de-
tecting interactions.
Recombinant protein expression and His-tag purification
All expression plasmids were sequence verified and re-
combinant proteins produced by transiently transfecting
HEK293-6E cells. Plasmids encoding bait proteins were
co-transfected with a plasmid encoding secreted BirA in
a 9:1 ratio as described [56]. HEK293-6E cells were
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maintained in Freestyle medium (Invitrogen) supple-
mented with 25 μg/mLG418 (Invitrogen) and 0.1%
Kolliphor. Transfections were left for 5 days, and super-
natants were harvested and filtered through a 0.2-μm fil-
ter. Supernatants containing prey proteins were used
neat or diluted without purification while those contain-
ing bait proteins were subjected to His-tag affinity purifi-
cation. Supernatants containing biotinylated bait
proteins were incubated with Ni-NTA agarose beads
(Jena Bioscience) overnight at 4 °C with constant rota-
tion. One hundred microliters of beads was used for
every 50 mL of supernatant. Polypropylene columns
(Qiagen) were equilibrated with 2 mL binding buffer (20
mM sodium phosphate buffer, 0.5 mM NaCl, 40 mM
imidazole) before addition of the bead-supernatant mix-
ture. Beads were washed with 5 mL binding buffer and
proteins eluted in 500 μL of elution buffer (20 mM so-
dium phosphate buffer, 0.5 mM NaCl, 400 mM imid-
azole) by incubating for 30 min at room temperature.
SDS-PAGE and Coomassie staining
To determine the purity and size of bait proteins, so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed under reducing conditions
with 10 μL of purified protein, followed by Coomassie
staining with InstantBLUE Protein Stain (Novus Biologi-
cals). Proteins were first denatured by boiling for 10 min
at 70 °C before gel electrophoresis using NuPAGE 4–
12% Bis-Tris Gels (Invitrogen) and MOPS buffer.
Tetramerization of biotinylated proteins
Bait protein concentrations were normalized to the
amount of protein needed to saturate 2 μg of streptavi-
din conjugated to PE (BioLegend). Streptavidin contains
four biotin-binding sites, allowing multiple biotinylated
bait proteins to be clustered around a single molecule of
streptavidin, thereby increasing the avidity of the oligo-
merized probe for potential binding partners. The con-
centration of biotinylated bait needed to saturate a fixed
amount of streptavidin-PE was determined by enzyme-
linked immunosorbent assay (ELISA).
Enzyme-linked immunosorbent assay
Serial dilutions of each bait protein were incubated with
or without 10 ng of streptavidin-PE overnight at 4 °C. The
remaining molecules of free biotinylated bait were cap-
tured on streptavidin-coated, flat-bottomed 96-well plates
(Nunc) for 45min at room temperature. Immobilized
baits were detected by a primary incubation with mono-
clonal mouse anti-rat CD4 IgG (OX68), which recognizes
a conformation-specific epitope on domains 3 and 4 of
CD4 present in the bait, followed by a secondary incuba-
tion with an alkaline phosphatase-conjugated anti-mouse
IgG (Bethyl Laboratories). All incubations were performed
for 1 h at room temperature, and plates were washed 3×
in PBS-0.1% Tween 20 and 1× in PBS between additions.
One hundred microliters of 1 μg/mL alkaline phosphatase
substrate (Sigma) dissolved in diethanolamine buffer
(0.5 mM MgCl2, 10% diethanolamine, pH 9.2) was
added to wells, and substrate hydrolysis after 15 min
was quantified by measuring absorbance at 405 nm
with a FLUOstar Optima plate reader (BMG Biotech).
Absorbance at 405 nm was plotted against dilution
factor for each bait protein and the highest concen-
tration at which no free biotinylated bait remained
after conjugation with streptavidin-PE was selected.
Genomic DNA extraction and sequencing
For samples with fewer than 1 × 106 cells, cells were resus-
pended in nuclease-free water at 8 × 105 cells/mL and lysed
for 10min at 95 °C. Lysates were treated with 2 μg/mL Pro-
teinase K for 50min at 55 °C followed by 10min at 95 °C
for inactivation. Ten microliters of treated lysate was used
as template for each 50 μL PCR reaction. For samples be-
tween 1 × 106–2 × 106 cells and 5 × 107–6 × 107 cells,
column-based purification of genomic DNA (gDNA) was
performed with DNeasy Blood and Tissue kit (Qiagen) and
Blood and Cell culture DNA maxi kit (Qiagen), respect-
ively. The DNA concentration in the eluate was quantified
with a NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientific) and 1–2 μg gDNA was used as template for
each 50 μL PCR reaction. Multiple individual PCR re-
actions (8–36) were performed to achieve sufficient
coverage of the library. A 298-bp fragment containing
the guide RNA sequence was amplified from gDNA.
Illumina adapters and barcodes were added in two
successive PCR reactions. Cycling conditions for both
reactions were as follows: 30 s at 98 °C for enzyme ac-
tivation, followed by a number of cycles of 10 s at 98
°C for denaturation, 15 s at 61 °C or 66 °C for primer
annealing (first and second reactions respectively), 15
s at 72 °C for extension, and a final extension for 2
min at 72 °C. Depending on the type of input
(column-purified gDNA or cell lysate), either 25 cycles
or 30 cycles were run for the first PCR reaction, re-
spectively. PCR products from the first reaction were
purified using Qiagen PCR purification kit and 1 ng
of purified product used as template in the second re-
action. The second PCR reaction involved 15 cycles of
amplification, after which PCR products were
size-selected using solid phase reversible immobilization
with Agencourt AmPure XP beads (Beckman Coulter) in
a 0.7 v/v ratio of beads to sample. 5 μL of PCR product
was analyzed with gel electrophoresis on a 2% agarose
gel to confirm for quantity and size after each reac-
tion. No template controls were performed to moni-
tor possible contamination from other sources.
Primers containing Illumina adaptors along with 11
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bp barcodes were used to allow for multiplexing of
up to 10 samples in a single run. Nineteen base pair
sequencing was performed with a custom sequencing
primer on a HiSeq 2500 in rapid run mode. All
primers used for Illumina library preparation and se-
quencing are listed in Additional file 1: Table S2.
CRISPRa screen analysis
Raw sequencing reads were converted from CRAM to
FASTQ format using the “fasta” function in SAMTools
1.3 (https://sourceforge.net/projects/samtools/files/sam-
tools/1.3/). The 19 bp reads were then aligned to gRNA
sequences using the count function in MAGeCK.
MAGeCK is a statistical package built for model-based
analysis of CRISPR screens and uses a mean-variance
function to estimate a null negative binomial distribution
for individual gRNA counts. For testing of gene level en-
richment, MAGeCK employs a modified Robust-Rank
Aggregation approach to evaluate the likelihood that
perturbing a particular gene is having an effect in a
pooled CRISPR screen [25]. Counts were normalized by
total number of reads to account for differences in se-
quencing depth. Enrichment testing was performed
using the test function in MAGeCK without further
normalization and with gRNAs grouped by gene rather
than TSS. The sequenced plasmid library was used as
the control sample for all tests. Using sequences from
unsorted libraries at day 7 or day 12 as the control sam-
ple gave similar results. Two genes (ITGB3 and
MEGF10) were excluded from all analyses except the
pooled antibody screens. This is due to contamination of
the sequencing libraries leading to inflated read counts
of several guides targeting MEGF10, while there was en-
richment of guides targeting ITGB3 in several screens
where an anti-αvβ3 antibody was included as a positive
control. All genes with a false discovery rate (FDR)
below 0.1 were considered candidate receptors and sec-
ondary validation performed with individually cloned
gRNA or overexpression with full-length cDNA encod-
ing the targeted receptor. All gRNA read count data are
provided in Additional file 4.
Annexin V staining
1 × 105 cells were washed 1× in PBS and 1× in binding
buffer for Annexin V staining (Invitrogen), before being
resuspended in 100 μL binding buffer. Five microliters
Annexin V-FITC (eBioscience) was added to 100 μL cell
suspension and incubated at room temperature for 10
min. Cells were then washed 1× with 2mL of binding
buffer and resuspended in 200 μl binding buffer for ana-
lysis. Five microliters of propidium iodide was added just
before analysis by flow cytometry.
Beta-lactamase-containing prey protein normalization
Prey proteins were normalized using beta-lactamase activ-
ity as a proxy by monitoring the time-resolved appearance
of the hydrolysis products of the beta-lactamase colori-
metric substrate, nitrocefin, which absorb at 485 nm. Ser-
ial dilutions of prey supernatants were made in PBS-1%
BSA and 20 μL of each dilution incubated with 60 μL of
125 μg/mL nitrocefin (Calbiochem) at room temperature.
Absorbance readings at 485 nm were taken once per mi-
nute for 20min and the dilution which caused complete
nitrocefin hydrolysis at 10mins was selected.
Avidity-based extracellular interaction screen (AVEXIS)
AVEXIS was performed essentially as described in [3].
Briefly, different dilutions of bait proteins were captured
on streptavidin-coated plates for 45 min at room
temperature. Plates were washed in PBS-1% Tween 20
and normalized prey proteins were added for 1 h at
room temperature. Excess prey protein was removed by
washing gently with PBS-1% Tween 20 twice and 60 μL
of 125 μg/mL nitrocefin added to detect captured prey
proteins. Absorbance readings at 485 nm were taken 1
and 2 h after nitrocefin addition. Either rCd200 and
rCd200R or hCD97 and hCD55 were used as positive
controls, and PBS-1% BSA added in place of either bait
or prey was used as a negative control.
Other statistical analyses
Student’s t test was performed in R.
Additional files
Additional file 1: Table S1. A table listing the gRNAs sequences
targeting the promoter regions for the named genes. The gene symbol,
accession number of the target transcript and chromosomal location are
provided. Table S2. A table detailing the sequences of the synthesized
DNA fragments and PCR primers used for plasmid construction and
sequencing, primers used for q-RT-PCR, and primers for gRNA library
preparation and amplification. Table S3. A table providing the sources,
and where appropriate, clone names of the primary monoclonal and
conjugated secondary antibodies used in this study. (PDF 553 kb)
Additional file 2: Figure S1. CRISPR activation enables rapid and stable
upregulation of cell surface proteins. Figure S2. A CRISPR activation
gRNA library targeting membrane-associated proteins. Figure S3.
Enrichment of gRNAs targeting known receptors in cells selected using
their corresponding ligand. Figure S4. ADGRB1 directly interacts with all
three members of the RTN4R family. (PDF 489 kb)
Additional file 3: A table detailing all the gRNA sequences present in
the CRISPRa library. For each named gene, the gRNA sequence is
provided together with the chromosomal location it targets and the
distance from the transcriptional start site (TSS). (CSV 4536 kb)
Additional file 4: A spreadsheet containing all the raw gRNA read
counts for each of the screens performed in this study. The gRNAs and
the gene promoter targeted are listed in the rows, and the experiments
in the columns: “plasmid” refers to the lentiviral gRNA library counts prior
to transformation; “d7” and “d12-transduced” refer to gRNA counts from
cells 7 and 12 days after transduction; “8aB_rep” to the three replicates
for the pooled monoclonal antibody screen; and the remaining columns
list the protein probes used for selection in the screens. (XLSX 5146 kb)
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